Regulation Certainty Needed to Boost Clinical ResearchBy Miriam Bello | Wed, 11/18/2020 - 15:54
Q: Why is CTI Clinical Trial and Consulting Services’ (CTI) model the best for the contract research market?
A: Since its foundation, CTI has been looking to innovate and transform the lives of patients suffering from chronic, clinical and orphan diseases. CTI’s organic growth has demonstrated how successful our model has been. We have worked on more than 6,000 research projects on almost all continents. CTI has contributed to the creation of more than 100 products according to the strict regulatory requirements of the FDA and EMA. We work with about 200 pharmaceutical companies that range from startups to Big Pharma companies. We work from Phase 1 research to more advanced clinical trials but we mostly focus on early stages.
Q: What role does Mexico play in the company’s global strategy?
A: Mexico’s large population plays a key role for our company. From working with both the public and private sectors, we have been able to reach many patients with our research projects, which is beneficial for our projects but mostly for participants. The data we have gathered from our work in Mexico is valuable to then be able to generate a solution for a specific group of patients. Moreover, by having participation in both sectors, we have been able to access different research centers and equipment, which is enriching for the projects.
CTI maintains close relationships with its clients and we always focus on aligning to their goals to reach the most beneficial outcome. CTI works with up-to-date technology to deliver excellent results to the client.
Q: Mexico’s potential as a research hub has been a popular subject within the healthcare sector. How could Mexico take advantage of its situation?
A: One long-time struggle is the uncertainty regarding approval processes. This is hard to explain to foreign companies that work with more scheduled regulatory processes and to sponsors that are very strict with their times. To avoid downtime, CTI has established strategies to use the waiting time to advance in other processes. Within this scenario, honesty is important, so we focus on explaining and contextualizing the regulatory situation of the country for the client.
Q: How has COVID-19 impacted demand for CTI’s services?
A: At a global level, we are working on 25 studies related to COVID-19. We never stopped working on our other projects, either. We want to continue growing globally and in Mexico. CTI is focused on complying with the highest quality of research while maintaining close contact with its clients.
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO) that provides clinical trial and consulting services at all stages of product development